Janus Henderson Group PLC Trims Stake in 10x Genomics $TXG

Janus Henderson Group PLC cut its position in 10x Genomics (NASDAQ:TXG) by 44.1% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 305,268 shares of the company’s stock after selling 240,558 shares during the quarter. Janus Henderson Group PLC’s holdings in 10x Genomics were worth $6,481,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Bull Harbor Capital LLC purchased a new stake in 10x Genomics in the first quarter valued at approximately $248,000. EverSource Wealth Advisors LLC increased its holdings in shares of 10x Genomics by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 7,186 shares of the company’s stock valued at $153,000 after acquiring an additional 1,012 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of 10x Genomics by 3.5% in the 1st quarter. The Manufacturers Life Insurance Company now owns 49,048 shares of the company’s stock valued at $1,041,000 after acquiring an additional 1,661 shares during the period. Quantinno Capital Management LP raised its position in 10x Genomics by 16.0% in the 1st quarter. Quantinno Capital Management LP now owns 5,411,761 shares of the company’s stock valued at $114,892,000 after purchasing an additional 744,558 shares during the last quarter. Finally, Caxton Associates LLP raised its position in 10x Genomics by 20.8% in the 1st quarter. Caxton Associates LLP now owns 14,552 shares of the company’s stock valued at $309,000 after purchasing an additional 2,508 shares during the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

10x Genomics Stock Performance

Shares of TXG opened at $45.60 on Friday. The stock has a market capitalization of $5.79 billion, a P/E ratio of -268.24 and a beta of 2.03. The company’s fifty day moving average is $38.81 and its two-hundred day moving average is $27.45. 10x Genomics has a 1 year low of $11.16 and a 1 year high of $50.34.

10x Genomics (NASDAQ:TXG) last released its earnings results on Thursday, August 6th. The company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.24) by $0.10. 10x Genomics had a negative net margin of 3.55% and a negative return on equity of 2.86%. The company had revenue of $151.04 million during the quarter, compared to analysts’ expectations of $146.67 million. The business’s revenue was down 12.7% on a year-over-year basis. During the same quarter last year, the business earned $0.28 EPS. Sell-side analysts predict that 10x Genomics will post -0.78 EPS for the current year.

Insider Activity

In other 10x Genomics news, Director Shehnaaz Suliman sold 5,723 shares of 10x Genomics stock in a transaction that occurred on Tuesday, June 16th. The stock was sold at an average price of $32.63, for a total value of $186,741.49. Following the sale, the director owned 31,722 shares of the company’s stock, valued at approximately $1,035,088.86. The trade was a 15.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $34.44, for a total value of $1,033,200.00. Following the transaction, the chief executive officer owned 1,108,380 shares in the company, valued at $38,172,607.20. The trade was a 2.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders sold 91,309 shares of company stock valued at $2,581,357. Company insiders own 8.84% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Piper Sandler raised their price objective on shares of 10x Genomics from $20.00 to $42.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 1st. Citigroup upped their target price on shares of 10x Genomics from $24.00 to $45.00 and gave the company a “neutral” rating in a report on Wednesday, July 8th. Leerink Partners raised their price target on 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a report on Friday, July 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a report on Wednesday, June 24th. Finally, TD Cowen restated a “hold” rating on shares of 10x Genomics in a research report on Wednesday, July 15th. Four research analysts have rated the stock with a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $32.08.

More 10x Genomics News

Here are the key news stories impacting 10x Genomics this week:

• Positive Sentiment: Adjusted loss was $0.14 per share, better than the consensus loss estimate of $0.24, while revenue of $151.0 million exceeded expectations of approximately $146.7 million. 10x Genomics Reports Q2 Loss, Tops Revenue Estimates
• Positive Sentiment: Management raised its full-year 2026 revenue outlook to $610 million-$630 million. The midpoint is broadly in line with the analyst consensus of $613.8 million, suggesting some improvement in visibility rather than a major forecast reset. 10x Genomics Raises 2026 Revenue Outlook
• Neutral Sentiment: Atera shipments remain at approximately 40 units, indicating continued customer adoption of the company’s newer spatial biology platform, although the update does not signal a significant acceleration in deployments. 10x Genomics Q2 2026 Earnings Call Transcript
• Negative Sentiment: Quarterly revenue declined 12.7% from the prior year, and the company remained unprofitable, reporting a net loss, negative net margin and negative return on equity. EPS also deteriorated from earnings of $0.28 in the year-earlier quarter to a loss of $0.14. 10x Genomics Reports Second Quarter 2026 Financial Results

About 10x Genomics

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.